Thrivent Financial for Lutherans Has $51.28 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Thrivent Financial for Lutherans trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 30.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 82,905 shares of the medical research company's stock after selling 36,714 shares during the period. Thrivent Financial for Lutherans' holdings in Thermo Fisher Scientific were worth $51,282,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of TMO. Lafayette Investments Inc. raised its position in shares of Thermo Fisher Scientific by 2.1% in the 2nd quarter. Lafayette Investments Inc. now owns 830 shares of the medical research company's stock worth $459,000 after buying an additional 17 shares during the period. IFG Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 3.3% in the 3rd quarter. IFG Advisors LLC now owns 532 shares of the medical research company's stock worth $329,000 after purchasing an additional 17 shares during the period. Patrick M Sweeney & Associates Inc. grew its holdings in shares of Thermo Fisher Scientific by 1.8% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,031 shares of the medical research company's stock worth $570,000 after purchasing an additional 18 shares during the period. Drive Wealth Management LLC increased its position in Thermo Fisher Scientific by 0.9% during the 2nd quarter. Drive Wealth Management LLC now owns 2,123 shares of the medical research company's stock worth $1,175,000 after purchasing an additional 18 shares in the last quarter. Finally, Quent Capital LLC raised its holdings in shares of Thermo Fisher Scientific by 1.0% during the 2nd quarter. Quent Capital LLC now owns 1,886 shares of the medical research company's stock valued at $1,043,000 after buying an additional 19 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,175,513.68. This represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the transaction, the senior vice president now owns 12,736 shares in the company, valued at $7,134,197.76. This represents a 13.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 37,150 shares of company stock valued at $20,651,865 over the last three months. 0.34% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on TMO shares. UBS Group upgraded Thermo Fisher Scientific to a "strong-buy" rating in a research note on Monday, September 16th. Barclays reduced their price objective on Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a research report on Wednesday, October 23rd. Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating for the company in a research report on Thursday, October 24th. Finally, Bernstein Bank boosted their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a "market perform" rating in a research report on Tuesday, October 22nd. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $649.33.

Thermo Fisher Scientific Trading Up 1.3 %

Shares of Thermo Fisher Scientific stock traded up $6.59 on Tuesday, reaching $507.88. 2,224,732 shares of the company were exchanged, compared to its average volume of 1,485,109. The stock has a fifty day moving average price of $584.05 and a 200-day moving average price of $581.90. The firm has a market capitalization of $194.26 billion, a price-to-earnings ratio of 31.44, a price-to-earnings-growth ratio of 3.39 and a beta of 0.79. Thermo Fisher Scientific Inc. has a fifty-two week low of $465.90 and a fifty-two week high of $627.88. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The business had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm's quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.69 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current year.

Thermo Fisher Scientific declared that its board has approved a share repurchase program on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.31%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.78%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.